EA201790967A1 - Химерные антигенные рецепторы против cldn и способы их применения - Google Patents

Химерные антигенные рецепторы против cldn и способы их применения

Info

Publication number
EA201790967A1
EA201790967A1 EA201790967A EA201790967A EA201790967A1 EA 201790967 A1 EA201790967 A1 EA 201790967A1 EA 201790967 A EA201790967 A EA 201790967A EA 201790967 A EA201790967 A EA 201790967A EA 201790967 A1 EA201790967 A1 EA 201790967A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
antigenous
chemical
receptors against
cldn
Prior art date
Application number
EA201790967A
Other languages
English (en)
Inventor
Пол Энтони Эскарп
Скотт Дж. Дилла
Роберт А. Сталл
Дэвид Лью
Original Assignee
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2014/064165 external-priority patent/WO2015069794A2/en
Application filed by ЭББВИ СТЕМСЕНТРКС ЭлЭлСи filed Critical ЭББВИ СТЕМСЕНТРКС ЭлЭлСи
Publication of EA201790967A1 publication Critical patent/EA201790967A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

Настоящее изобретение относится к новым химерным антигенным рецепторам против CLDN и способам их применения для лечения пролиферативных нарушений.
EA201790967A 2014-11-05 2015-11-04 Химерные антигенные рецепторы против cldn и способы их применения EA201790967A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US2014/064165 WO2015069794A2 (en) 2013-11-06 2014-11-05 Novel anti-claudin antibodies and methods of use
US201562157928P 2015-05-06 2015-05-06
US201562247108P 2015-10-27 2015-10-27
PCT/US2015/059106 WO2016073649A1 (en) 2014-11-05 2015-11-04 Anti-cldn chimeric antigen receptors and methods of use

Publications (1)

Publication Number Publication Date
EA201790967A1 true EA201790967A1 (ru) 2017-10-31

Family

ID=55909771

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790967A EA201790967A1 (ru) 2014-11-05 2015-11-04 Химерные антигенные рецепторы против cldn и способы их применения

Country Status (23)

Country Link
US (1) US20170334991A1 (ru)
EP (1) EP3215523A4 (ru)
JP (1) JP2017535283A (ru)
KR (1) KR20170085531A (ru)
CN (1) CN107207580A (ru)
AU (1) AU2015343079A1 (ru)
BR (1) BR112017009517A2 (ru)
CA (1) CA2966618A1 (ru)
CL (1) CL2017001118A1 (ru)
CO (1) CO2017005538A2 (ru)
CR (1) CR20170235A (ru)
DO (1) DOP2017000110A (ru)
EA (1) EA201790967A1 (ru)
EC (1) ECSP17031725A (ru)
IL (1) IL252090A0 (ru)
MA (1) MA40921A (ru)
MX (1) MX2017005797A (ru)
PE (1) PE20171060A1 (ru)
PH (1) PH12017500825A1 (ru)
SG (1) SG11201703669YA (ru)
TW (1) TW201625677A (ru)
WO (1) WO2016073649A1 (ru)
ZA (1) ZA201703471B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201603397QA (en) * 2013-11-06 2016-05-30 Stemcentrx Inc Novel anti-claudin antibodies and methods of use
US20190263927A1 (en) * 2016-10-14 2019-08-29 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
WO2019065964A1 (ja) 2017-09-29 2019-04-04 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
CN113164408A (zh) * 2018-12-07 2021-07-23 科济生物医药（上海）有限公司 肿瘤联合免疫治疗
JP2022524906A (ja) * 2019-01-07 2022-05-11 クレージュ メディカル カンパニー，リミテッド 細胞免疫療法の組み合わせ
US20210347847A1 (en) * 2020-05-11 2021-11-11 The Broad Institute, Inc. Therapeutic targeting of malignant cells using tumor markers
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
KR20230154317A (ko) * 2021-03-05 2023-11-07 상하이 젠베이스 바이오테크놀로지 씨오., 엘티디. 항-cldn6 항체 및 이의 용도
CN114478802B (zh) * 2022-01-28 2023-05-26 郑州大学 一种嵌合抗原受体及其应用
WO2024088325A1 (zh) * 2022-10-25 2024-05-02 科济生物医药（上海）有限公司 抗体及其应用
CN117169518B (zh) * 2023-11-03 2024-01-19 赛德特(北京)生物工程有限公司 T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101074261A (zh) * 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
CN101951953A (zh) * 2007-02-27 2011-01-19 株式会社未来创药研究所 含抗grp78抗体作为有效成分的药物组合物
US9274119B2 (en) * 2008-01-11 2016-03-01 The University Of Tokyo Anti-CLDN6 antibody
KR102126964B1 (ko) * 2009-11-11 2020-06-25 가니메드 파마슈티칼스 게엠베하 클라우딘 6 특이적 항체
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
EP2970426B1 (en) * 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
SG11201603397QA (en) * 2013-11-06 2016-05-30 Stemcentrx Inc Novel anti-claudin antibodies and methods of use
JP6726656B2 (ja) * 2014-04-01 2020-07-22 バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｃｅｌｌ ＆ Ｇｅｎｅ Ｔｈｅｒａｐｉｅｓ Ｇｍｂｈ クローディン６特異的免疫受容体およびｔ細胞エピトープ
WO2016180467A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
CN108473588A (zh) * 2015-12-04 2018-08-31 艾伯维施特姆森特克斯有限责任公司 新颖抗密封蛋白抗体及使用方法

Also Published As

Publication number Publication date
MX2017005797A (es) 2017-10-23
CR20170235A (es) 2017-07-21
KR20170085531A (ko) 2017-07-24
PE20171060A1 (es) 2017-07-21
AU2015343079A1 (en) 2017-05-25
ECSP17031725A (es) 2017-06-30
WO2016073649A1 (en) 2016-05-12
PH12017500825A1 (en) 2017-10-18
TW201625677A (zh) 2016-07-16
CL2017001118A1 (es) 2018-01-05
IL252090A0 (en) 2017-07-31
CO2017005538A2 (es) 2017-10-10
ZA201703471B (en) 2019-06-26
CA2966618A1 (en) 2016-05-12
US20170334991A1 (en) 2017-11-23
SG11201703669YA (en) 2017-06-29
BR112017009517A2 (pt) 2017-12-19
MA40921A (fr) 2017-09-12
JP2017535283A (ja) 2017-11-30
CN107207580A (zh) 2017-09-26
DOP2017000110A (es) 2017-05-31
EP3215523A4 (en) 2018-06-20
EP3215523A1 (en) 2017-09-13

Similar Documents

Publication Publication Date Title
PH12017501521A1 (en) Anti-dll3 chimeric antigen receptors and methods of use
EA201790967A1 (ru) Химерные антигенные рецепторы против cldn и способы их применения
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201791208A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
GEP20217331B (en) Anti-tigit antibodies
MY192927A (en) Fused bicyclic compounds for the treatment of disease
DK3594238T3 (da) Antistofsammensætninger til tumorbehandling
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
EA201691541A1 (ru) Новые анти-baff антитела
EA201691367A1 (ru) Кристаллические формы дималеата афатиниба
IL251587A0 (en) Treatment of urological disorders with selective androgen receptor modulators (sarms)
IL249393A0 (en) Methods for treating conditions with antibodies that bind colony-stimulating factor receptor 1 (csf1r)
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose
MA54630A (fr) N,n-bis-2-mercaptoéthyle isophtalamide pour le traitment des maladies neurodégénératives
NZ744340A (en) Anti-jagged1 antibodies and methods of use
TH1601001388A (th) สารเพื่อลดแคแทบอลิซึมหรือกระตุ้นแอนาบอลิซึมของโปรตีน
TH1501004159A (th) วิธีการของการใช้งานของสารประกอบฟีนอกซีโพรพิลเอมีน เพื่อบำบัดภาวะซึมเศร้า